Anbu Liu

SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib

Hui Zhao, R. Bai, Jianmin Sun, 2023, Gastric Cancer.

DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors

Shaoting Zhang, Liangying Zhang, Sien Zhao, 2023, Molecular carcinogenesis.

Four and a half LIM domains 2 (FHL2) attenuates tumorigenesis of gastrointestinal stromal tumors (GISTs) by negatively regulating KIT signaling

Shaoting Zhang, Liangying Zhang, Zongying Jiang, 2024, Molecular carcinogenesis.